Andersons pediatric cardiology 2355
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (100.62 KB, 3 trang )
Greatcardiacvein,31,31f
Groundsubstance,1356
Groupedbeating,337–338
Growth
failureof,mechanismsof
growthfactorhormone,1496
hypermetabolism,1495–1496
inadequatecaloricintake,1495
malabsorption,1496
followingcardiactransplantation,1238
physical,assessmentof,1496
Growthfactors
cardiacdevelopmentand,51
growthand,1496
GuangdongRegistryofCongenitalHeartDisease,1511t–1514t
Guidewires,forinterventionaltechniques,255
H
Haloperidol,forcarditis,1017t
Hammockmitralvalve,611
Harm,researchstudieson,criticalappraisalof,420–421
Headcircumference,1498t
Headultrasonography,ofcentralnervoussystem,inFontanpathway,1291
Healthcaredata,403
Health-relatedqualityoflife,incomplexcongenitalcardiacdisease,1403–1404
Healthstatusandhealth-relatedqualityoflife(HRQOL),1459
Healthsystemchallenges,inlow-andmiddle-incomecountries,1521–1523,
1521b
acquiredheartdisease,1522–1523
congenitalheartdisease,1521–1522,1522t
Heart
abnormalpositions,913–926
criss-crossortwisted,920–926,920f–926f
embryologyof,33–47,Cardiacembryology
exteriorizationof,913–915,914f–915f
andheart-lungtransplantation,1217–1239
ABO-incompatible,1222f,1226
adultcare,transitionto,1238
aerobiccapacityand,1235–1236
allograftvasculopathyand,1232–1233,1232f
riskfactorsanddiagnosisof,1225t,1232,1233f–1234f
treatmentof,1233
assessmentpriorto,1221–1223,1224b
contraindicationsto,1224–1226
developmentand,1238
donorfor,1227–1228
exerciseand,1235–1236
functionalstatusand,1238
futuredirectionsfor,1239
growthand,1238
HLAsensitizationand,1226–1227
hypertensionfollowing,1238–1239
immunosuppressionfor,1229,1230f
indicationsfor,1223–1224,1224b
infectionsfollowing,1236–1237
listingfor,duringfetallife,1226–1227
withlungtransplantation,1238–1239
lymphoproliferativedisordersfollowing,1225t,1237–1238,1237f,1237t
mechanicalsupportasbridgeto,1224f,1227,1227f–1228f
monitoringandsurveillanceafter,1229–1238
non-adherencetotherapyand,1238
outcomeswith,1217–1221
causesofdeathand,1221,1225t,1226f
mortalitywhileawaitingtransplantationand,1217–1218
riskfactorsfordeathand,1219–1220,1224t–1225t
survivalaftertransplantationand,1218–1219,1222f–1224f
post-operativecomplicationsof,1229
posttransplanteducationand,1229
psychosocialissuesand,1238
qualityoflifeand,1238
recipientmanagementand,1229
referralpatternsanddemographicsof,1217,1218f–1221f
rejectionand,1225t,1226f,1231f–1232f
renalfunctionfollowing,1237
retransplantationand,1234,1234f–1236f
specialconsiderationsin,1226–1227
surgicaltechniquesfor,1228–1229
normalandthefailing,functionof,1193–1196,1194f
positionof,inisomericatrialappendages,449
relationshipsof,913–926
asserviceorgan,381–382,382f
surgicalviewof,313
Heartfailure,1426–1427
cardiacmyocytein,1197–1198
chronic,1193–1203
inchronicrheumaticheartdisease,1032
treatmentof,144
Heartfields,60f
Heartrate
cardiacoutputand,382,382f
fetal,83
variabilityof,103–104,104f–105f
maturationalchangesand,83
Heartsound
inEbsteinmalformation,591
ininteratrialcommunication,511
Hearttransplantpatients,indiagnosticcatheterization,251–252
Hearttransplantation
forcardiactumors,977
exercisetestingfollowing,401
timingof,forFontanfailure,1347–1348
Hearttube,embryologyof,33,34f
HeartMateII,inlong-termmechanicalcirculatorysupport,1209
HeartWareHVAD(Medtronic),1209
Hemangioma,927–928,974
